- Home
- ADXN vs QNRX Comparison
ADXN vs QNRX Comparison
Compare ADXN & QNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ADXN | QNRX |
|---|---|---|
| Founded | 2002 | 2018 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.6M | 10.1M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ADXN | QNRX |
|---|---|---|
| Price | $8.44 | $13.98 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 8.0K | ★ 101.4K |
| Earning Date | 12-04-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $198,824.00 | N/A |
| Revenue This Year | $86.57 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.51 | $5.01 |
| 52 Week High | $12.05 | $41.80 |
Technical Indicators
Market Signals| Indicator | ADXN | QNRX |
|---|---|---|
| Relative Strength Index (RSI) | 52.16 | 49.30 |
| Support Level | $7.47 | $9.68 |
| Resistance Level | $8.30 | $14.90 |
| Average True Range (ATR) | 0.45 | 2.10 |
| MACD | 0.06 | -0.21 |
| Stochastic Oscillator | 72.22 | 39.95 |
Price Performance
Historical ComparisonAbout ADXN Addex Therapeutics Ltd
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.
About QNRX Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.